{"id":"convalescent-plasma","safety":{"commonSideEffects":[{"rate":null,"effect":"Transfusion-related acute lung injury (TRALI)"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Circulatory overload"},{"rate":null,"effect":"Transfusion-transmitted infection"}]},"_chembl":{"chemblId":"CHEMBL2108772","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Convalescent plasma is collected from individuals who have recovered from a specific infection and contains pathogen-specific antibodies and other immune components. When transfused into acutely ill patients, these antibodies provide immediate passive immunity to help neutralize the pathogen and modulate the immune response. This approach leverages the donor's adaptive immune response to support the recipient's own immune system during acute infection.","oneSentence":"Convalescent plasma transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against infectious disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:21.445Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (severe or life-threatening disease)"},{"name":"Emerging infectious diseases (investigational)"}]},"trialDetails":[{"nctId":"NCT04333251","phase":"PHASE1","title":"Study Testing Convalescent Plasma vs Best Supportive Care","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2020-04-17","conditions":"Pneumonia, Interstitial","enrollment":""},{"nctId":"NCT04411602","phase":"PHASE1","title":"Intermediate IND Severe Illness COVID-19 CP","status":"WITHDRAWN","sponsor":"Henry Ford Health System","startDate":"2020-04-07","conditions":"Severe Acute Respiratory Syndrome, COVID","enrollment":""},{"nctId":"NCT04497779","phase":"","title":"Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-07-13","conditions":"Asymptomatic COVID-19 Infection Laboratory-Confirmed, Symptomatic COVID-19 Infection Laboratory-Confirmed","enrollment":95},{"nctId":"NCT04803370","phase":"NA","title":"Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma","status":"COMPLETED","sponsor":"Hospital Son Llatzer","startDate":"2020-07-08","conditions":"Covid19","enrollment":55},{"nctId":"NCT02338986","phase":"","title":"Collection of Plasma From People Who Recovered From or Were Vaccinated to Emerging Infectious Diseases","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-03-04","conditions":"Communicable Diseases, Communicable Diseases, Emerging, Emerging Infectious Diseases","enrollment":10},{"nctId":"NCT06590207","phase":"PHASE3","title":"Convalescent Plasma for the Treatment of Patients With WNV - a Double- Blind Randomized Controlled Study","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2024-07-04","conditions":"West Nile Fever With Neurologic Manifestation (Diagnosis), West Nile Fever Without Complications","enrollment":200},{"nctId":"NCT04345523","phase":"PHASE2","title":"Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients","status":"COMPLETED","sponsor":"Cristina Avendaño Solá","startDate":"2020-04-03","conditions":"COVID-19","enrollment":350},{"nctId":"NCT04408209","phase":"NA","title":"Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2020-04-23","conditions":"COVID-19 Infection","enrollment":60},{"nctId":"NCT04558476","phase":"PHASE2","title":"Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation","status":"COMPLETED","sponsor":"University of Liege","startDate":"2020-09-11","conditions":"Covid19, Mechanical Ventilation Complication, Corona Virus Infection","enrollment":475},{"nctId":"NCT05271929","phase":"PHASE3","title":"Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19","status":"TERMINATED","sponsor":"Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","startDate":"2022-04-01","conditions":"COVID-19","enrollment":120},{"nctId":"NCT04513158","phase":"PHASE2","title":"Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection","status":"TERMINATED","sponsor":"Joseph M. Flynn, D.O., MPH","startDate":"2020-08-14","conditions":"Covid19","enrollment":2},{"nctId":"NCT04359810","phase":"PHASE2","title":"Plasma Therapy of COVID-19 in Severely Ill Patients","status":"COMPLETED","sponsor":"Max O'Donnell","startDate":"2020-04-21","conditions":"SARS-CoV-2 Infection","enrollment":223},{"nctId":"NCT04390503","phase":"PHASE2","title":"Convalescent Plasma for Early Treatment of COVID-19","status":"TERMINATED","sponsor":"Andrew Eisenberger","startDate":"2021-03-12","conditions":"SARS-CoV 2, COVID-19","enrollment":223},{"nctId":"NCT04973488","phase":"NA","title":"Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients","status":"COMPLETED","sponsor":"Novacescu Alexandru","startDate":"2020-07-25","conditions":"COVID-19 Pneumonia, COVID-19 Respiratory Infection, Acute Respiratory Failure","enrollment":38},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04345991","phase":"PHASE2","title":"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-15","conditions":"Covid19","enrollment":120},{"nctId":"NCT04516954","phase":"EARLY_PHASE1","title":"Convalescent Plasma for COVID-19 Patients","status":"COMPLETED","sponsor":"Vinmec Research Institute of Stem Cell and Gene Technology","startDate":"2020-08-01","conditions":"COVID 19","enrollment":4},{"nctId":"NCT04521036","phase":"PHASE1","title":"Convalescent Plasma for COVID-19 Patients (CPCP)","status":"COMPLETED","sponsor":"Vinmec Research Institute of Stem Cell and Gene Technology","startDate":"2020-12-01","conditions":"COVID 19","enrollment":4},{"nctId":"NCT04397523","phase":"NA","title":"Efficacy and Safety of COVID-19 Convalescent Plasma","status":"COMPLETED","sponsor":"Institute for Transfusion Medicine of RNM","startDate":"2020-04-30","conditions":"Convalescent Plasma, COVID-19, SARS-CoV 2","enrollment":200},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT04351503","phase":"","title":"A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-04-09","conditions":"SARS Coronavirus (SARS-CoV-2) Infection","enrollment":126586},{"nctId":"NCT04354831","phase":"PHASE2","title":"Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2020-05-11","conditions":"COVID-19","enrollment":131},{"nctId":"NCT04545047","phase":"","title":"Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2020-05-01","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":5044},{"nctId":"NCT04377672","phase":"PHASE1","title":"Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-05-28","conditions":"SARS-CoV-2 Infection","enrollment":14},{"nctId":"NCT04340050","phase":"EARLY_PHASE1","title":"COVID-19 Convalescent Plasma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2020-04-10","conditions":"Coronavirus","enrollment":10},{"nctId":"NCT04360278","phase":"","title":"Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2020-04-21","conditions":"COVID-19","enrollment":258},{"nctId":"NCT04355897","phase":"EARLY_PHASE1","title":"CoVID-19 Plasma in Treatment of COVID-19 Patients","status":"COMPLETED","sponsor":"The Christ Hospital","startDate":"2020-04-28","conditions":"COVID 19","enrollment":22},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT04956445","phase":"","title":"Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development","status":"UNKNOWN","sponsor":"Tulane University","startDate":"2020-03-17","conditions":"Covid19","enrollment":2000},{"nctId":"NCT04463823","phase":"","title":"\"NORPLASMA\" Covid-19 Convalescent Plasma Treatment Monitoring Study","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2020-07-06","conditions":"COVID","enrollment":500},{"nctId":"NCT04412486","phase":"EARLY_PHASE1","title":"COVID-19 Convalescent Plasma (CCP) Transfusion","status":"COMPLETED","sponsor":"Gailen D. Marshall Jr., MD PhD","startDate":"2020-06-01","conditions":"COVID-19","enrollment":86},{"nctId":"NCT05077930","phase":"PHASE2","title":"Convalescent Plasma Therapy for Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Tânia Portella Costa","startDate":"2022-01-06","conditions":"COVID-19, Convalescent Plasma, SARS-CoV-2","enrollment":38},{"nctId":"NCT04420988","phase":"","title":"Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients","status":"NO_LONGER_AVAILABLE","sponsor":"Rutgers, The State University of New Jersey","startDate":"","conditions":"COVID-19, SARS-CoV 2, SARS-CoV Infection","enrollment":""},{"nctId":"NCT06084351","phase":"PHASE3","title":"Phase 3 Open-Label Controlled Trial of Convalescent Plasma in Early COVID-19 Infection","status":"WITHDRAWN","sponsor":"Larkin Community Hospital","startDate":"2020-05-12","conditions":"Covid19","enrollment":""},{"nctId":"NCT04456413","phase":"PHASE2","title":"Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2020-11-06","conditions":"COVID-19","enrollment":21},{"nctId":"NCT04343755","phase":"PHASE2","title":"Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2020-04-09","conditions":"COVID-19","enrollment":52},{"nctId":"NCT04433910","phase":"PHASE2","title":"A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19","status":"COMPLETED","sponsor":"Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","startDate":"2020-08-30","conditions":"COVID-19","enrollment":106},{"nctId":"NCT05157165","phase":"","title":"Convalescent Plasma in Hospitalized COVID-19 Patients","status":"NO_LONGER_AVAILABLE","sponsor":"Azienda Socio Sanitaria Territoriale di Mantova","startDate":"","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05905380","phase":"","title":"Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment of Immunocompromised Patients","status":"UNKNOWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2023-03-02","conditions":"COVID-19 Convalescent Plasma Treatment","enrollment":200},{"nctId":"NCT05904067","phase":"NA","title":"A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-06-10","conditions":"COVID-19, Hematopoietic Stem Cell Transplantation","enrollment":72},{"nctId":"NCT04373460","phase":"PHASE2","title":"Convalescent Plasma to Limit SARS-CoV-2 Associated Complications","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-06-03","conditions":"SARS-CoV 2","enrollment":1225},{"nctId":"NCT04445207","phase":"","title":"Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19","status":"NO_LONGER_AVAILABLE","sponsor":"Jonathan Gerber","startDate":"","conditions":"COVID, Sars-CoV2, Corona Virus Infection","enrollment":""},{"nctId":"NCT04360486","phase":"","title":"Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)","status":"NO_LONGER_AVAILABLE","sponsor":"U.S. Army Medical Research and Development Command","startDate":"","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2","enrollment":""},{"nctId":"NCT04334876","phase":"NA","title":"Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers","status":"COMPLETED","sponsor":"Indiana University","startDate":"2020-04-01","conditions":"SARS-CoV-2","enrollment":571},{"nctId":"NCT04434131","phase":"PHASE2","title":"Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2020-04-28","conditions":"COVID-19","enrollment":12},{"nctId":"NCT04363034","phase":"","title":"Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program","status":"NO_LONGER_AVAILABLE","sponsor":"University of Arkansas","startDate":"","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04884477","phase":"","title":"COVID-19 Infection in Patients Receiving Anti-CD20 Therapy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-06-01","conditions":"COVID-19, Immunosuppressed Host, Convalescent Plasma","enrollment":342},{"nctId":"NCT05745753","phase":"NA","title":"Clinical and Imaging Biomarkers Associated With Plasma ad Cellular Determinants of Cardiovascular Disease at the Time of COVID 19","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-01-16","conditions":"Cardiovascular Diseases","enrollment":120},{"nctId":"NCT04364737","phase":"PHASE2","title":"CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-04-17","conditions":"COVID-19, Coronavirus, Coronavirus Infection","enrollment":941},{"nctId":"NCT04408040","phase":"PHASE2","title":"Use of Convalescent Plasma for COVID-19","status":"TERMINATED","sponsor":"Northside Hospital, Inc.","startDate":"2020-07-14","conditions":"COVID","enrollment":8},{"nctId":"NCT04362176","phase":"PHASE3","title":"Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2020-04-24","conditions":"COVID-19, Coronavirus, SARS-CoV-2","enrollment":974},{"nctId":"NCT05595538","phase":"EARLY_PHASE1","title":"Use of Multiple Doses of Convalescent Plasma in Mechanically Intubated Patients With COVID-19","status":"COMPLETED","sponsor":"Hospital Regional Dr. Rafael Estévez","startDate":"2020-06-06","conditions":"COVID-19","enrollment":30},{"nctId":"NCT04555109","phase":"","title":"Convalescent Plasma for COVID-19 Research Donor Study","status":"UNKNOWN","sponsor":"The Hospital for Sick Children","startDate":"2020-06-30","conditions":"Covid19","enrollment":1000},{"nctId":"NCT04891172","phase":"PHASE2, PHASE3","title":"Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients","status":"UNKNOWN","sponsor":"Dow University of Health Sciences","startDate":"2021-08-01","conditions":"Covid19","enrollment":310},{"nctId":"NCT05578391","phase":"PHASE2","title":"Passive Immunotherapy In Patients With SARS CoV-2","status":"COMPLETED","sponsor":"Fundacin Biomedica Galicia Sur","startDate":"2020-01-01","conditions":"COVID-19","enrollment":61},{"nctId":"NCT04472572","phase":"","title":"Expanded Access to Convalescent Plasma for Treatment of COVID-19","status":"NO_LONGER_AVAILABLE","sponsor":"Hackensack Meridian Health","startDate":"","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04421404","phase":"PHASE2","title":"Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients","status":"COMPLETED","sponsor":"Priscilla Hsue, MD","startDate":"2020-06-09","conditions":"COVID-19, Sars-CoV2","enrollment":34},{"nctId":"NCT04539275","phase":"PHASE3","title":"VA CoronavirUs Research and Efficacy Studies-1","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2020-11-16","conditions":"COVID-19","enrollment":75},{"nctId":"NCT04382651","phase":"PHASE2","title":"Study of Efficacy and Safety of MAS825 in Patients With COVID-19","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-11","conditions":"COVID-19 Pneumonia, Impaired Respiratory Function","enrollment":140},{"nctId":"NCT04345289","phase":"PHASE3","title":"Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia","status":"TERMINATED","sponsor":"Thomas Benfield","startDate":"2020-05-01","conditions":"COVID, Corona Virus Infection, Viral Pneumonia","enrollment":147},{"nctId":"NCT04382053","phase":"PHASE2","title":"Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-05-27","conditions":"COVID-19 Pneumonia, Impaired Respiratory Function","enrollment":143},{"nctId":"NCT04404608","phase":"","title":"Etiology of Lymphopenia in Covid19 Infection","status":"COMPLETED","sponsor":"Dr Medhat Khafagy","startDate":"2020-06-01","conditions":"Lymphopenia","enrollment":172},{"nctId":"NCT04535063","phase":"PHASE3","title":"Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno","startDate":"2020-04-18","conditions":"Covid19 Pneumonia","enrollment":200},{"nctId":"NCT04730401","phase":"PHASE2","title":"Convalescent Plasma in the Treatment of Covid-19","status":"UNKNOWN","sponsor":"Helsinki University Central Hospital","startDate":"2021-01-27","conditions":"Covid19","enrollment":390},{"nctId":"NCT04567173","phase":"PHASE2, PHASE3","title":"Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19","status":"TERMINATED","sponsor":"University of the Philippines","startDate":"2020-09-21","conditions":"Covid19","enrollment":44},{"nctId":"NCT04415086","phase":"PHASE2","title":"Treatment of Patients With COVID-19 With Convalescent Plasma","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-06-01","conditions":"COVID-19","enrollment":129},{"nctId":"NCT04385199","phase":"PHASE2","title":"Convalescent Plasma for Patients With COVID-19","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2020-05-04","conditions":"Coronavirus Infection, Coronavirus, COVID","enrollment":30},{"nctId":"NCT04323800","phase":"PHASE2","title":"Convalescent Plasma to Stem Coronavirus (CSSC-001)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-06-10","conditions":"Coronavirus, Convalescence","enrollment":180},{"nctId":"NCT04397757","phase":"PHASE1","title":"COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-05-13","conditions":"COVID-19","enrollment":80},{"nctId":"NCT04372979","phase":"PHASE3","title":"Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.","status":"TERMINATED","sponsor":"Direction Centrale du Service de Santé des Armées","startDate":"2020-09-14","conditions":"COVID-19","enrollment":18},{"nctId":"NCT04438057","phase":"PHASE2","title":"Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19","status":"COMPLETED","sponsor":"Metro Infectious Disease Consultants","startDate":"2020-08-12","conditions":"COVID-19","enrollment":103},{"nctId":"NCT04366245","phase":"PHASE1, PHASE2","title":"Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection","status":"COMPLETED","sponsor":"Andalusian Network for Design and Translation of Advanced Therapies","startDate":"2020-04-23","conditions":"SARS-CoV 2","enrollment":72},{"nctId":"NCT04642014","phase":"NA","title":"Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness","status":"TERMINATED","sponsor":"Wroclaw Medical University","startDate":"2020-12-22","conditions":"COVID-19 Convalescent Plasma Treatment","enrollment":396},{"nctId":"NCT04388527","phase":"PHASE1","title":"COVID-19 Convalescent Plasma for Mechanically Ventilated Population","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-04-30","conditions":"Covid-19","enrollment":32},{"nctId":"NCT04374565","phase":"PHASE2","title":"Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2020-05-05","conditions":"Corona Virus Infection, SARS-CoV 2, SARS Pneumonia","enrollment":29},{"nctId":"NCT04589949","phase":"PHASE3","title":"Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2020-10-12","conditions":"Covid19","enrollment":420},{"nctId":"NCT04342182","phase":"PHASE2, PHASE3","title":"Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2020-04-08","conditions":"COVID-19","enrollment":86},{"nctId":"NCT04721236","phase":"NA","title":"Early Use of Hyperimmune Plasma in COVID-19","status":"UNKNOWN","sponsor":"Catherine Klersy","startDate":"2020-11-19","conditions":"Covid19","enrollment":260},{"nctId":"NCT04432272","phase":"PHASE2","title":"ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)","status":"TERMINATED","sponsor":"Corewell Health East","startDate":"2020-07-16","conditions":"COVID-19, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections","enrollment":71},{"nctId":"NCT05247307","phase":"PHASE3","title":"Efficacy of the Infusion of Donor Plasma in COVID-19 Infection","status":"TERMINATED","sponsor":"Hospital Galdakao-Usansolo","startDate":"2020-03-31","conditions":"COVID-19","enrollment":93},{"nctId":"NCT04348656","phase":"PHASE3","title":"CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)","status":"TERMINATED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2020-03-14","conditions":"COVID-19","enrollment":940},{"nctId":"NCT04428021","phase":"PHASE2","title":"Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure","status":"COMPLETED","sponsor":"A.O.U. Città della Salute e della Scienza","startDate":"2020-06-15","conditions":"COVID-19","enrollment":180},{"nctId":"NCT04681430","phase":"PHASE2","title":"Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2021-01-08","conditions":"Corona Virus Infection, SARS-CoV-2 Infection, SARS-CoV-2 PCR Test Positive","enrollment":22},{"nctId":"NCT04649879","phase":"PHASE2, PHASE3","title":"Convalescent Plasma for Treatment of COVID-19","status":"COMPLETED","sponsor":"Joakim Dillner","startDate":"2020-12-03","conditions":"Covid19","enrollment":59},{"nctId":"NCT05200754","phase":"PHASE2","title":"Trial With or Without Infusion of SARS-CoV-2 Antibody Containing Plasma in High-Risk Patients With COVID-19","status":"UNKNOWN","sponsor":"Carsten Müller-Tidow","startDate":"2020-09-03","conditions":"SARS-CoV-2 Infection","enrollment":174},{"nctId":"NCT05184127","phase":"PHASE2","title":"Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19","status":"COMPLETED","sponsor":"National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia","startDate":"2021-04-27","conditions":"COVID-19","enrollment":156},{"nctId":"NCT04502472","phase":"PHASE2, PHASE3","title":"Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma","status":"TERMINATED","sponsor":"Inova Health Care Services","startDate":"2020-06-06","conditions":"Covid-19","enrollment":109},{"nctId":"NCT04390178","phase":"PHASE1, PHASE2","title":"Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)","status":"COMPLETED","sponsor":"Joakim Dillner","startDate":"2020-04-10","conditions":"COVID-19","enrollment":10},{"nctId":"NCT04392232","phase":"PHASE2","title":"A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection","status":"COMPLETED","sponsor":"TriHealth Inc.","startDate":"2020-05-05","conditions":"Coronavirus, COVID-19, Convalescent Plasma","enrollment":159},{"nctId":"NCT04344535","phase":"PHASE1, PHASE2","title":"Convalescent Plasma vs. Standard Plasma for COVID-19","status":"TERMINATED","sponsor":"Stony Brook University","startDate":"2020-04-08","conditions":"COVID","enrollment":82},{"nctId":"NCT04524507","phase":"PHASE2","title":"Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2020-08-27","conditions":"COVID-19","enrollment":56},{"nctId":"NCT04384497","phase":"PHASE1, PHASE2","title":"Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study","status":"COMPLETED","sponsor":"Joakim Dillner","startDate":"2020-05-07","conditions":"COVID-19","enrollment":10},{"nctId":"NCT04458363","phase":"EARLY_PHASE1","title":"Convalescent Plasma in Pediatric COVID-19","status":"COMPLETED","sponsor":"Emory University","startDate":"2020-07-04","conditions":"COVID","enrollment":3},{"nctId":"NCT04347681","phase":"PHASE2","title":"Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19","status":"COMPLETED","sponsor":"King Fahad Specialist Hospital Dammam","startDate":"2020-04-18","conditions":"Convalescent Plasma for COVID 19","enrollment":575},{"nctId":"NCT04353206","phase":"EARLY_PHASE1","title":"Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure","status":"TERMINATED","sponsor":"Noah Merin","startDate":"2020-06-27","conditions":"Covid-19, Sars-CoV2","enrollment":6},{"nctId":"NCT04497324","phase":"PHASE2","title":"PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19","status":"COMPLETED","sponsor":"Universidad Peruana Cayetano Heredia","startDate":"2020-09-21","conditions":"COVID-19","enrollment":100},{"nctId":"NCT04429854","phase":"PHASE2","title":"Donated Antibodies Working Against nCoV","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-05-02","conditions":"COVID-19","enrollment":483},{"nctId":"NCT04356534","phase":"NA","title":"Convalescent Plasma Trial in COVID -19 Patients","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2020-04-19","conditions":"SARS-CoV 2, COVID-19","enrollment":40},{"nctId":"NCT04355767","phase":"PHASE3","title":"Convalescent Plasma in Outpatients With COVID-19","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-08-11","conditions":"Covid19","enrollment":511},{"nctId":"NCT04425915","phase":"PHASE3","title":"Efficacy of Convalescent Plasma Therapy in Patients With COVID-19","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2020-06-14","conditions":"COVID","enrollment":400}],"_emaApprovals":[],"_faersSignals":[{"count":272,"reaction":"OFF LABEL USE"},{"count":76,"reaction":"DRUG INEFFECTIVE FOR UNAPPROVED INDICATION"},{"count":45,"reaction":"DRUG INEFFECTIVE"},{"count":43,"reaction":"COVID-19"},{"count":42,"reaction":"RESPIRATORY FAILURE"},{"count":25,"reaction":"MATERNAL EXPOSURE DURING PREGNANCY"},{"count":23,"reaction":"ACUTE KIDNEY INJURY"},{"count":22,"reaction":"COVID-19 PNEUMONIA"},{"count":22,"reaction":"DEATH"},{"count":21,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"}],"_approvalHistory":[],"publicationCount":2363,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Plasma therapy","Plasma","Not appicable","no apply","Fresh Frozen Plasma (FFP)"],"phase":"phase_3","status":"active","brandName":"Convalescent Plasma","genericName":"Convalescent Plasma","companyName":"Hackensack Meridian Health","companyId":"hackensack-meridian-health","modality":"Biologic","firstApprovalDate":"","aiSummary":"Convalescent plasma transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against infectious disease. Used for COVID-19 (severe or life-threatening disease), Emerging infectious diseases (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":31,"withResults":10},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}